1. The Preserflo MicroShunt was evaluated for efficacy and safety in primary open-angle glaucoma.
2. Researchers observed a significant reduction in intraocular pressure and medication burden, especially in normal-pressure glaucoma.
3. Limitations included short follow-up period and lack of medication washout period.
4. The researchers concluded that MicroShunt implantation has a positive benefit-to-risk ratio.

Source: Journal of Glaucoma